What We Do?
Every M&A deal. Every key metric. All in one place.
Spitzer Data is a live M&A intelligence platform covering announced deals, active situations, and historical precedents across North America, Europe, and Asia-Pacific.
Track deals with:
• Live break prices & closing odds
• Real-time news, filings & market data
• Regulatory timelines & key milestones
• Fair value, offer premiums & trading analytics
• Searchable precedents by industry, regulator, advisor, transaction type & more
Whether you're evaluating an acquisition, researching comparable transactions, modeling merger arbitrage, or tracking a live deal, Spitzer Data gives you the data and analytics to make faster, more informed decisions.
Follow for daily M&A insights, deal updates, and market intelligence.
https://t.co/K7PE3GkuFv
Interested in the possibility of Chipotle ($CMG) becoming an acquisition target? the median premium across 17 comparable food-industry deals in Spitzer Data is 31.9%.
What premium do you think it would take to get $CMG?
For UK PUSU situations, Spitzer Data plots Rule 8.3 disclosed long and short positions directly against the share price.
Search by investor or company to see how positions have changed as the situation develops.
Look at the full graph on https://t.co/WcyT3lR7Wi
$QGEN
While CTFN (@ctfn_news ) reporting suggests a potential takeout price in discussions of around $50 per share, Spitzer Data metrics show a potential valuation range up to the low 60’s.
Use our tools to easily generate your own estimates based on your chosen assumptions.
#corpfin #mergers
$MGM trading below its beta-adjusted break price while potentially having the opportunity to retire 27% of its shares through a discounted block acquisition.
Add in the largely unrecognized value of the Osaka, Japan asset and the risk/reward looks increasingly asymmetric… 🤷♂️
Following an M&A deal should be easy.
Here's how Spitzer Data's Live Metrics page brings live pricing, spreads, break prices, closing odds, etc. into one view.
Take a look ↓
Does your work touch M&A?
Save time daily with our tools.
Spitzer Data’s truly unique M&A database with dated, regulator driven events and outcomes has what you need.
Every deal we track carries a structured history of each agency's actions — FTC/DOJ second requests, EC Phase I/II, CMA Phase 2, SAMR, CFIUS, FSR — that you can screen instantly by event type, date range, sector, status and EV.
Do you want to find "recent second requests in non-therapeutic healthcare"?
This could take you a dozen web searches to assemble publicly. Fetch the output in seconds with Spitzer Data.
The five most recent second requests in non-therapeutic healthcare (services, devices, distribution, staffing — no pharma/biotech) are, for example:
1. Cencora (MWI Animal Health) / Covetrus — FTC second request, May 2026. $3.5B animal-health distribution merger; would cut national vet distributors from three to two. $COR
2. Boston Scientific / Penumbra — FTC second request, March 16, 2026. Medical devices (vascular/neuro). HSR filed Feb 13, second request ~30 days later. $PEN $BSX
3. Alcon / LENSAR — FTC second request, May 21, 2025. Ophthalmic surgical devices (laser cataract systems). $ALC $LEN
4. CrossCountry Healthcare / Aya Healthcare — FTC second request, February 20, 2025. Nurse staffing. (The deal ultimately died.) $CCRN
5. Owens & Minor / Rotech — FTC second request, October 11, 2024. $1.36B home medical equipment deal — terminated in 2026 after regulatory clearance "proved unviable."
Get the list with a few keystrokes. You can prompt in plain language.
Same goes for other regulatory histories, such as CFIUS (seven dated clearance events this year, for example, across energy, gaming, insurance and media), which can be found instantly.
For law and finance broadly, Spitzer Data is the most universally useful single tool for public company M&A.
For investors, along with precedent info, find one-line live deal summaries and full one-page situation summaries, tracking and analysis. See relevant spreads, break prices, instant market-implied probability of any live deal closing, comps, closing date estimates, and more.
#mergers #corpfin
Total value of ongoing deals per target sector:
Consumer, Retail & Leisure: $276.9B
Energy & Resources: $253.9B
Media: $159.0B
Healthcare & Life Sciences: $153.7B
Industrials: $145.9B
With all the attention on Media M&A this year, are you surprised it isn't higher on the list?
Media M&A banker league table since 2022. Top acquirer financial advisors ranked by total EV. Centerview and RedBird being on the list isn’t too surprising given the size of the $WBD / $PSKY merger.
Which firms will take on the next big media deal?
$WBD/$PSKY
Warner Bros. Discovery is up after the states challenging the merger reached a settlement with the companies.
The deal is now trading at just a 1.5% gross spread following the news. Just over a month ago, that spread was 20.6%.
Notice what is happening in $ZIM / Hapag-Lloyd …
The offer is $35.00. The stock trades at $30.10 — a 16% discount.
The discount likely reflects the posture of the Israeli government towards the sale. A revised Hapag-Lloyd/FIMI proposal to the Government Companies Authority is due by end-September 2026, and expected to be put to Israel's cabinet this month.
Meantime, could the company actually be worth more without a deal? The implied break price — where $ZIM will land if the deal dies — is estimated by Spitzer Data using our standard methodology at $38.25, or above the deal’s consideration.
While the estimate could be off - our comps rely on our proprietary algo though users can adjust our model in seconds with suggested revisions or with their own assumptions and re-run - it seems nevertheless clear that should the deal proceed, Hapag-Lloyd is getting a bargain, based on how comps have traded since the deal was announced and present valuation for container shipping companies.
Hapag-Lloyd may have bought the cheapest large-cap in shipping. This should mean as a buyer it is very committed to figuring out how to manage the remedy process it is attempting to negotiate with the Israeli government.
#mergers #corpfin
The UK Competition and Markets Authority has opened a Phase 1 investigation into the AkzoNobel (AKZA:NA) / Axalta ($AXTA) merger.
Spitzer Data currently calculates a $26.85 break price for $AXTA, derived using both technical price movements and valuation analysis from our selected comparable companies.
See the comparables, methodology and live deal metrics, and have the opportunity to add your own on https://t.co/291OrFBFBm.
What a difference 1.5 months makes.
The $WBD / $PSKY gross spread has tightened from 20.6% to 10.6%.
For a deal of this size, that’s a significant move, and a sign the market is increasingly pricing in a successful close.
Follow deal trends live on https://t.co/VBwHXiEoCV
📌 Deal Update
With a March trial now on the calendar, the $WBD / $PSKY deal is trading at a 20.6% gross spread as investors price in additional legal and timing risk.
Monitor live spreads, break prices, and closing odds on Spitzer Data
Warner Bros/Paramount:
Our algorithm swapped out DISH for CHTR in the comp set (the 43% attributable to cable & satellite TV comps) post Cox/Charter, but this contributed to moving the estimated break price down from $7.76 to $7.19.
Is it a reasonable swap?
The Spitzer Data platform allows you to use pre-loaded comps from our industry classification framework or swap out your own, and vary your other assumptions as well.
Presently the all-in annualized spread to the estimated closing date of June 1 is 17.5% vs gross downside of 74%, suggesting market-implied odds of closing are 85%, notwithstanding the states’ lawsuit.
These odds are roughly flat from mid August. But again, you can adjust assumptions on our platform per your own research and recalculate.
$WBD $PSKY #mergers #corpfin